Nuvalent Stock (NASDAQ:NUVL), Trade Ideas

Nuvalent

Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Biotech

Small Cap

Exclusives

Tech

Trading Ideas

General

ATEN

Merrill Lynch & Strategic Return Notes for Select 10 Index

NUVL

RIVN

Investors are constantly on the hunt for undervalued, under-followed and emerging stocks. With countless methods available to retail traders, the challenge often lies in sifting through the abundance to uncover new information.

Benzinga&#39;s &#39;Stock Whisper&#39; Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet

News

Health Care

Initiation

Analyst Ratings

Movers

Stifel initiated coverage on Nuvalent Inc (NASDAQ: NUVL), recognizing that adopting a bullish stance in anticipation of Phase 1 cancer drug data, mainly when derived from heavily pretreated patients, has proven unprofitable for approximately two years. 

Challenging Road Ahead for Cancer Drugs, Nuvalent Seeks to Break the Mold

Penny Stocks

Intraday Update

Markets

AENZ

AGRI

AMPX

ATNF

AVGR

AWIN

AYRO

CABA

CARA

CATX

CBUS

CFRX

CHSN

DCGO

ELWS

EOSE

FOXO

GPRE

IOVA

LIFW

MCOM

MIRA

MRDB

MTNB

NEXI

NKLA

OKYO

PCSA

SCLX

SEZL

SHOT

SSKN

TENX

TPHS

TTOO

UPTD

VANI

WORX

ZAPP

Why Nikola Shares Are Trading Higher By 33%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Nuvalent Inc

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Privia Health Group (PRVA – Research Report) and Nuv...

Analysts' Top Healthcare Picks: Privia Health Group (PRVA), Nuvalent (NUVL)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Esperion (ESPR – Research Report) and Nuvalent (NUVL...

Analysts' Top Healthcare Picks: Esperion (ESPR), Nuvalent (NUVL)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Nuvalent (NUVL – Research Report) and Arcutis Biothe...

Analysts Offer Insights on Healthcare Companies: Nuvalent (NUVL) and Arcutis Biotherapeutics (ARQT)

Big Pharma patent cliffs seen fueling oncology M&A this year

Cantor Fitzgerald sees strong year ahead for oncology M&A

Cantor sees strong year ahead for oncology M&A

Nuvalent Inc (NUVL) stock has gained 3.17% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator. Nuvalent Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on NUVL!See Full NUVL ReportWhat is Stock Sentiment?When making investment decis

Do Traders Think Nuvalent Inc (NUVL) Can Keep Climbing Wednesday?

Nuvalent Inc (NUVL) is around the top of the Biotechnology industry according to InvestorsObserver. NUVL received an overall rating of 63, which means that it scores higher than 63 percent of all stocks. Nuvalent Inc also achieved a score of 72 in the Biotechnology industry, putting it above 72 percent of Biotechnology sto

Is Nuvalent Inc (NUVL) a Good Choice in Biotechnology Monday?

The 80 rating InvestorsObserver gives to Nuvalent Inc (NUVL)  stock puts it near the top of the Healthcare sector.In addition to scoring higher than 74 percent of stocks in the Healthcare sector, NUVLâ€&#x2122;s 80 overall rating means the stock scores better than 80 of all stocks. NUVL has an Overall Score of 80. Find out what thi

Should You Add Nuvalent Inc (NUVL) Stock to Your Portfolio Monday?

Jefferies starts Nuvalent at buy, cites lung cancer drug candidates

ALXO

AMAM

ARQT

ARVN

BCYC

CGON

DAWN

DCPH

ERAS

ESPR

EXEL

FUSN

GERN

HARP

IDYA

IMCR

IMTX

JANX

KPTI

KURA

LEGN

MRUS

OLMA

ORIC

PMVP

PRVA

RLAY

RVMD

SNDX

SWTX

URGN

VSTM

ZNTL

Press Releases

Nuvalent Reports Preliminary Phase 1 Clinical Data from ALKOVE-1 Trial that Support Best-In-Class Potential of NVL-655 for Patients with ALK-Positive NSCLC

Earnings

Nuvalent Highlights Corporate and Pipeline Achievements and Reports Third Quarter 2023 Financial Results

Nuvalent to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Nuvalent Announces "OnTarget 2026" Operating Plan and Key Anticipated Milestones

Nuvalent to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Nuvalent Initiates the Phase 2 Portion of ALKOVE-1 Clinical Trial for Patients with ALK-Positive NSCLC and other Solid Tumors

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520

Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial Results

Nuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024

Nuvalent Presents New Preclinical Data Supporting Profiles of HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, Zidesamtinib, at AACR Annual Meeting 2024

Alkermes

Alpine Immune Sciences, Inc. - Common Stock

Alpine Immune Sciences

Alvotech

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

BridgeBio Pharma

Biohaven

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Crinetics Pharmaceuticals, Inc. - Common Stock

Crinetics Pharmaceuticals

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exelixis

Amicus Therapeutics

Grifols, S.A. - American Depositary Shares

Grifols

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

ImmunityBio

Immunovant

Insmed

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals

Iovance Biotherapeutics, Inc. - Common Stock

Iovance Biotherapeutics

Krystal Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Vaxcyte

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

SpringWorks Therapeutics, Inc. - common stock

SpringWorks Therapeutics

Viking Therapeutics

Jefferies

Leerink Partners

JP Morgan

Guggenheim

BMO Capital